A Phase 3 interventional study of No PMRT for mastectomy / No regional RT for BCS and PMRT for mastectomy / WBI + Regional RT for BCS in Radiotherapy and Breast Cancer, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.
Sponsored by Seoul National University Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.
Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one is the 2nd largest by planned enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 14 of the 20 other live ones, and was the 40th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 40–69 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 19 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 5 · Phase 4 1
First in 2006; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,106 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 114 across the 28 interventional studies, 352 across the 22 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
3 of the studies in Breast Neoplasms by Seoul National University Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05440149Phase 3Seoul National University HospitalThe Postoperative Radiotherapy in N1 Breast Cancer Patients | 2026-12-31 |
| NCT03594396Seoul National University HospitalWindow of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer | 2026-12-31 |
| NCT04892693Seoul National University HospitalTalazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, phase 3 clinical trial in patients with breast cancer, randomizing radiotherapy group (postmastectomy radiation therapy (PMRT)/whole breast irradiation plus regional radiotherapy (WBI+regional RT) versus and no PMRT/WBI alone group. This is a non-inferiority study aiming that there is no significant difference in the 7-year disease-free survival rate between the two groups.
1:1 randomization to the control group and experimental group, stratified by the type of surgery (breast-conserving surgery (BCS) versus mastectomy) and the type of histologic type (triple negative breast cancer (TNBC) versus non-TNBC)
The control group:
The experimental group:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with stage pN1 after surgery on histopathologic examination.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* If patients received mastectomy, post-mastectomy radiation therapy (PMRT) should be performed. * If patients received breast conserving surgery (BCS), whole breast irradiation (WBI) + Regional radiotherapy (RT) should be performed.
Radiation: PMRT for mastectomy / WBI + Regional RT for BCS
* If patients received mastectomy, No PMRT should be performed. * If patients received BCS, WBI alone should be performed.
Radiation: No PMRT for mastectomy / No regional RT for BCS
* Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
* Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
Disease-Free Survival
Time from randomization to local recurrence, regional recurrence, distant metastases, or breast cancer-related death.
Time frame: 7-Year
Locoregional-Recurrence Free Survival
Time from randomization to recurrence of tumors in the ipsilateral chest wall, breast or regional lymph nodes (ipsilateral axillary/internal mammary/supraclavicular lymph nodes) or breast cancer-related death. \*\* Recurrence should be confirmed by histological diagnosis, but local recurrence can be diagnosed by clinical examination only when regional/remote or distant metastases already exist.
Time frame: 7-Year
Distant Metastases Free Survival
Time from randomization to the development of distant metastases or breast cancer-related death.
Time frame: 7-Year
Overall Survival
Time from randomization to the death due to any cause.
Time frame: 7-Year
Dermatitis
Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Scale
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Radiation-related pneumonitis
Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Scale
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Major complication rate for reconstructed breast
For patients who received breast reconstruction after mastectomy
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Occurence of contralateral in-situ or invasive breast cancer
Pathologic confirmation
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Major cardiac event
Myocardial infarction / Ischemic heart failure / Unstable angina / Sudden death
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Ipsilateral rib fracture
Symptom or radiologic diagnosis
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Arm Lymphedema
Symptom / Diagnosis from the related-department (e.g. rehab) / Expert opinion
Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization
Plan to share: No
Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 52 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →